| A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers (NCT03258515) | AstraZeneca | 2017-09-06 |
| Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (NCT03252938) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2017-08-15 |
| Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (NCT03313778) | ModernaTX, Inc. | 2017-08-14 |
| Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors (NCT02587962) | Medivir | 2017-08-04 |
| A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) (NCT03235570) | Incyte Corporation | 2017-08-01 |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies (NCT03144661) | Incyte Corporation | 2017-05-25 |
| Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors (NCT03101488) | 3D Medicines (Sichuan) Co., Ltd. | 2017-03-21 |
| Ceramide NanoLiposome in Patients With Advanced Solid Tumors (NCT02834611) | Keystone Nano, Inc | 2017-03-15 |
| Study of Ixazomib and Erlotinib in Solid Tumors (NCT02942095) | M.D. Anderson Cancer Center | 2017-03-06 |
| Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer (NCT02216669) | Maastricht Radiation Oncology | 2017-03-01 |
| Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors (NCT03065062) | Dana-Farber Cancer Institute | 2017-02-28 |
| Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas (NCT03030417) | National Cancer Institute (NCI) | 2017-02-27 |
| Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) (NCT02959437) | Incyte Corporation | 2017-02-27 |
| A Study Evaluating MM-310 in Patients With Solid Tumors (NCT03076372) | Merrimack Pharmaceuticals | 2017-02-22 |
| Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms (NCT03006029) | Theramab LLC | 2017-02-08 |
| Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) (NCT03010176) | Merck Sharp & Dohme LLC | 2017-02-03 |
| Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors (NCT02827968) | 3D Medicines (Sichuan) Co., Ltd. | 2017-01-13 |
| Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors (NCT03006887) | Eisai Co., Ltd. | 2017-01-12 |
| ODM-207 in Patients With Advance Solid Tumours (NCT03035591) | Orion Corporation, Orion Pharma | 2016-12-22 |
| Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies (NCT02620839) | Pamela Munster | 2016-12-01 |
| A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (NCT02797795) | Neovia Oncology Ltd. | 2016-12-01 |
| Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors (NCT02988817) | Genmab | 2016-11-23 |
| A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors (NCT02674555) | Astellas Pharma Global Development, Inc. | 2016-11-15 |
| Kanitinib in Treating Patients With Advanced Solid Tumors (NCT02916095) | Beijing Konruns Pharmaceutical Co., Ltd. | 2016-11-01 |
| A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors (NCT02705963) | Novartis Pharmaceuticals | 2016-10-20 |
| Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (NCT02789228) | Children's National Research Institute | 2016-10-12 |
| A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors (NCT02536183) | AeRang Kim | 2016-10-01 |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (NCT02909452) | Syndax Pharmaceuticals | 2016-09-20 |
| Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors (NCT02903914) | Incyte Corporation | 2016-09-14 |
| A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies) (NCT02828930) | Hoffmann-La Roche | 2016-09-08 |
| Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides (NCT02890368) | Pfizer | 2016-09-01 |
| A Phase I Trial of HS-10241 in Solid Tumors (NCT02759640) | Atridia Pty Ltd. | 2016-09-01 |
| Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors (NCT02897778) | Syndax Pharmaceuticals | 2016-08-24 |
| A Study of ERY974 in Patient With Advanced Solid Tumors (NCT02748837) | Chugai Pharmaceutical | 2016-08-01 |
| MASCT-I Treatment for Advanced Solid Tumor (NCT02858232) | The First People's Hospital of Lianyungang | 2016-08-01 |
| Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas (NCT02740270) | Novartis Pharmaceuticals | 2016-07-22 |
| Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) (NCT02761694) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2016-06-26 |
| PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) (NCT02702492) | Karyopharm Therapeutics Inc | 2016-06-08 |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors (NCT02759666) | Atridia Pty Ltd. | 2016-06-01 |
| Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors (NCT02746081) | Bayer | 2016-05-26 |
| Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors (NCT02762981) | Corcept Therapeutics | 2016-05-23 |
| Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (NCT02639546) | Hoffmann-La Roche | 2016-05-20 |
| Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies (NCT02711137) | Incyte Corporation | 2016-05-18 |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (NCT02632448) | Esperas Pharma Inc. | 2016-05-16 |
| Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer (NCT02719691) | University of Colorado, Denver | 2016-05-13 |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (NCT02650401) | Hoffmann-La Roche | 2016-05-03 |
| Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes (NCT02680795) | Acrotech Biopharma Inc. | 2016-04-27 |
| Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies (NCT02721043) | Nina Bhardwaj | 2016-04-01 |
| Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore) (NCT02766842) | Johns Hopkins University | 2016-04-01 |
| MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors (NCT02699515) | Merck KGaA, Darmstadt, Germany | 2016-03-11 |
| A Study of Kyphoplasty and Vertebroplasty in the Treatment of Spine Metastases (NCT02700308) | Centre Leon Berard | 2016-03-01 |
| A Study of PLX51107 in Advanced Malignancies (NCT02683395) | Plexxikon | 2016-03-01 |
| Study of JS001 in Participants With Advanced Solid Tumors (NCT02857166) | Shanghai Junshi Bioscience Co., Ltd. | 2016-03-01 |
| A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors (NCT02881138) | RemeGen Co., Ltd. | 2016-03-01 |
| A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors (NCT02667873) | Stemline Therapeutics, Inc. | 2016-02-23 |
| Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer (NCT02546531) | Washington University School of Medicine | 2016-02-03 |
| The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors (NCT02660034) | BeiGene | 2016-02-02 |
| CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) (NCT02675946) | Curegenix Inc. | 2016-02-01 |
| A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (NCT02673736) | Plexxikon | 2016-02-01 |
| Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors (NCT02646748) | Incyte Corporation | 2016-01-25 |
| A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (NCT02593786) | Bristol-Myers Squibb | 2016-01-07 |
| A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors (NCT02650713) | Hoffmann-La Roche | 2016-01-07 |
| Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients (NCT07631611) | Wenlong Zhong, MD | 2016-01-01 |
| Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas (NCT02661542) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2016-01-01 |
| Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab (NCT02628574) | Leap Therapeutics, Inc. | 2016-01-01 |
| Study of INCB053914 in Subjects With Advanced Malignancies (NCT02587598) | Incyte Corporation | 2015-12-29 |
| Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors (NCT02426892) | M.D. Anderson Cancer Center | 2015-12-23 |
| Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors (NCT02881190) | RemeGen Co., Ltd. | 2015-12-14 |
| The Oral Cavity as a Source of Febrile Neutropenia (NCT02702583) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2015-12-01 |
| Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors (NCT02537561) | Washington University School of Medicine | 2015-12-01 |
| Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment (NCT02619045) | Institut Claudius Regaud | 2015-11-09 |
| A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (NCT02597036) | Eli Lilly and Company | 2015-11-06 |
| A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors (NCT02556463) | MedImmune LLC | 2015-11-04 |
| Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors (NCT02559492) | Incyte Corporation | 2015-11-01 |
| A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma (NCT02608125) | Principia Biopharma, a Sanofi Company | 2015-10-28 |
| An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. (NCT02598960) | Bristol-Myers Squibb | 2015-10-14 |
| The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor (NCT03641586) | BeiGene | 2015-10-12 |
| Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors (NCT02648711) | NewLink Genetics Corporation | 2015-10-01 |
| URMC Related Haplo-identical Donor BMT (NCT02660281) | University of Rochester | 2015-10-01 |
| A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours (NCT02521844) | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | 2015-10-01 |
| A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (NCT02630368) | Institut Bergonié | 2015-09-18 |
| 3 Tesla Magnetic Resonance Guided High Intensity Focused Ultrasound in the Treatment of Pain From Bone Metastases of Solid Tumors (NCT02718404) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2015-09-14 |
| Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors (NCT02451007) | PharmaMar | 2015-08-12 |
| Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors (NCT02478866) | Betta Pharmaceuticals Co., Ltd. | 2015-08-11 |
| Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (NCT02498912) | Memorial Sloan Kettering Cancer Center | 2015-08-01 |
| A Study of CriPec® Docetaxel Given to Patients With Solid Tumours (NCT02442531) | Cristal Therapeutics | 2015-08-01 |
| A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene (NCT02506517) | University Health Network, Toronto | 2015-08-01 |
| MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors. (NCT02503774) | MedImmune LLC | 2015-07-24 |
| Registry Study for Personalized Cancer Therapy (NCT02508662) | M.D. Anderson Cancer Center | 2015-07-21 |
| Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas (NCT02503423) | Taiho Oncology, Inc. | 2015-07-14 |
| Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy (NCT02499224) | CellabMED | 2015-07-13 |
| A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors (NCT02350673) | Hoffmann-La Roche | 2015-06-29 |
| Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole (NCT02476955) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2015-06-09 |
| Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors (NCT02423057) | National Cancer Institute (NCI) | 2015-05-18 |
| Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors (NCT02379416) | National Cancer Institute (NCI) | 2015-04-13 |
| ADC-1013 First-in-Human Study (NCT02379741) | Alligator Bioscience AB | 2015-04-01 |
| Investigator Initiated Phase 1 Study of TBI-1301 (NCT02366546) | Mie University | 2015-03-01 |
| Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours (NCT02303028) | The Hospital for Sick Children | 2015-03-01 |
| A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types (NCT02296879) | Young Suk Park | 2015-01-20 |
| Oral ONC201 in Treating Patients With Advanced Solid Tumors (NCT02250781) | Rutgers, The State University of New Jersey | 2015-01-12 |